By Bhanvi Satija and Pushkala Aripaka LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker ...
NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC”), today ...
Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
Regarding the industry's talent pipeline, Dr. de Miguel highlights the importance of education programs in the fields of science, technology, engineering, and mathematics (STEM) in building the ...
Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of ...
Explore the debate surrounding animal testing as new methods may jeopardise patient safety if not properly validated.
There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...
AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.
Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty ...
As China's new drug R&D enters the 'deep waters' of homogeneous competition, the path for followers has become increasingly ...
According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results